Omics Global Solutions (OGS) borne as a company whose objective is to be the platform for development and launch of products related to "omics" sciences (proteomics, genomics, metabolomics, metagenomics, etc.) associated with innovative projects that have an impact on the lives of patients, their caregivers and medical professionals involved in their treatment.
Located in Puerto Rico (USA), it's
first milestone is the manufacturing and commercialization of one ELISA assay (DIATRACK2™) based on Biomarkers discovered and patented by Proteomics International for the prognosis of Diabetic Kidney Disease (DKD) using the license of the patented technology PromarkerD™ to cover the population of the Dominican Republic located in the Caribbean and later expand its footprint to the rest of Latin-america among other markets.
Being a Biotechnology company with development and commercial skills Omics is always open and seeking for strategic alliances for novel technologies with clear impact in the diagnostic field.
